News

Saint Luke’s Mid America Heart Institute was the first in Kansas and Missouri, and one of only 27 US institutions, to participate in PULSED AF clinical trial.

We are talking about lung cancer and how precision oncology helps patients diagnosed with the disease with treatment.

Dr. Tim Pluard, medical director of Saint Luke’s Koontz Center for Advanced Breast Cancer and of Saint Luke’s Cancer Institute, talks about innovative treatment options for breast cancer and clinical trials offered at Saint Luke’s.

We’re talking about how younger women and men can monitor for breast cancer and recent updates in screening guidelines.

A man from Columbia, Missouri, got a new heart and a second chance at life, marking the 1,000th heart transplant at Saint Luke's Mid America Heart Institute.

This week during Breast Cancer Awareness Month, we’re talking about metastatic breast cancer and Saint Luke’s Koontz Center—the region’s only center dedicated and designed specifically for these patients.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.